P
Photys Therapeutics
A proprietary chimeric small molecules platform company, developing a new class of medicines for precise control of protein function
About Photys Therapeutics
Photys Therapeutics is a biotech startup that operates in the pharmaceutical industry, focusing on the development of bifunctional small molecules. These molecules are designed to control protein post-translational modifications, a process that can restore protein function, repair signaling, and amplify the body's natural disease-fighting mechanisms. This innovative approach goes beyond traditional degradation methods, offering a new way to tackle diseases at a molecular level.
The company was co-founded by Amit Choudhary, a leading bifunctional chemist from the Broad Institute, and the Longwood Fund. It also boasts a scientific advisory board composed of esteemed scientists and drug developers from institutions such as MIT, Salk, Berkeley, MPM, and Dana Farber.
Photys Therapeutics' primary product is Phosphorylation-Inducing Chimeric Small Molecules (PHICS). These molecules are designed to precisely modulate and repair disease-driving proteins, offering a potential breakthrough in the treatment of various diseases.
The company recently secured $75 million in Series A funding, indicating strong investor confidence in its business model and scientific approach. This funding will be used to advance the development and testing of its bifunctional molecules.
Photys Therapeutics operates on a business model common in the biotech industry. It invests in research and development to create innovative pharmaceutical products. Once these products are approved for use, the company generates revenue by selling them to healthcare providers and patients.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Sep 2022 | $75M | $300M | Merck & Co. · 8VC · Eli Lilly · Mass General Brigham Ventures | ↗ |
Growth signals
Latest recorded traffic for Photys Therapeutics is 960 monthly website visits, down 61.6% over the last three months. Photys Therapeutics's team declined 44.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Photys Therapeutics in the Waltham ecosystem
The Photys Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A10 investors entered at this stage
MPM BioImpact
Merck & Co.
8VC
Eli Lilly
Mass General Brigham Ventures
Longwood Fund
Arkin CapitalOmega Funds
MRL Ventures- HSHeritage Medical Systems
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Photys Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Photys Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










